1.0 **Purpose:** This standard operating practice (SOP) establishes guidelines for planned emergency research where it is anticipated that a waiver of consent will be required because subjects will not be able to provide consent or where a Legally Authorized Representative (LAR) will be unavailable. This SOP will address the responsibilities of both the investigator and the UMCIRB regarding planned emergency research.

2.0 **Research Protocols Affected:** This SOP affects planned emergency research reviewed and approved by the Biomedical UMCIRB (both single site and multi-center) in which waiver of consent is requested and for which an ECU or ECU affiliate’s faculty, staff, or student serves on the research team.

3.0 **SOP:** This SOP is to ensure the Biomedical UMCIRB meets its responsibilities for the review, approval, and oversight of clinical investigations that require an exception from informed consent requirements for planned emergency research. These actions must be decided at a convened meeting and should include plans for consultation with the community from which the targeted population will be recruited. Every effort should be made on the part of the investigator to obtain informed consent from the subject, or their LAR, at the earliest possible opportunity.

Protocols involving an exception to the informed consent requirement must be performed under a separate investigational new drug application (IND) or investigational device exemption (IDE) that clearly identifies such protocols as those that may include individuals who are unable to consent. The submission of those protocols in a separate IND/IDE is required even if an IND or an IDE already exists.

4.0 **Definitions:**

4.1 **Emergency research:** is planned research with humans in a life-threatening situation for which available treatments are unproven or unsatisfactory, and the collection of valid scientific evidence is necessary to determine the safety and effectiveness of particular interventions. These are situations where it is not feasible to obtain prospective informed consent from the subject, or their LAR, and participation in the research holds out the prospect of direct benefit to the subject. It is research that has received prospective IRB approval and;

4.1.1 may include drugs, devices, and biologics that are not approved for marketing or are not approved for emergency situations in which the investigator proposes to use them;

4.1.2 subjects are not able to give informed consent due to their medical condition;

4.1.3 the window of time in which the intervention must be administered does not allow for informed consent from the subject or the subject’s LAR; and

4.1.4 there is no reasonable way to prospectively identify individuals likely to become eligible for participation.

4.2 **Waiver of informed consent:** research is conducted without obtaining prospective consent from the subject or their LAR and may be requested by the investigator due to the nature of planned emergency research.
4.2.1 **Exceptions:** Because of special regulatory limitations relating to research involving prisoners (subpart C of 45 CFR part 46), and research involving fetuses, pregnant women, and human in vitro fertilization (subpart B of 45 CFR part 46), this waiver is inapplicable to these categories of research.

4.3 **Community consultation:** providing the opportunity for discussions with, and soliciting opinions from, the community in which the study will take place and the community from which the study subjects will be drawn. These communities may not always be the same; when they are not the same, both communities should be consulted. The goals of community consultation are to:

4.3.1 show respect for persons by informing the community about the study in advance;

4.3.2 inform community members about the trial in advance and provide a means for affected communities to provide meaningful input to the IRB before its decision to approve, require modifications to, or disapprove the study;

4.3.3 show respect for the community by allowing representatives of the community to identify potential community-level concerns and effects of the research; and

4.3.4 show respect for subjects’ autonomy. Respect may be shown by including in community consultation activities individuals who may have, or be at risk for, the condition under study (and thereby obtain input from a group that is expected to be similar to the eventual study subjects).

4.4 **Community in which the research will be conducted:** the geographic area, e.g., hospital or other facility, or city or region, where the hospital or clinical investigator study site is located.

4.5 **Community from which subjects will be drawn (i.e., the community at risk):** the group of patients who share a particular medical or other characteristic that increases the likelihood that they (or a family member) may be enrolled in the study.

4.6 **Legally Authorized Representative (LAR):** is defined as an individual or judicial or other body authorized under applicable law to consent on behalf of a potential study participant to his or her participation in the procedure(s) involved in the research.

5.0 **Responsibilities:**

5.1 **Investigator** responsibilities include:

5.1.1 Submission of a request to waive informed consent inclusive of the rationale for the waiver request within the IRB application.

5.1.2 Consultation with representatives of the communities from which subjects will be drawn and providing a summary of results/discussion/concerns to the IRB.

5.1.3 Public disclosure to the communities in which the research will be conducted and from which the subjects will be drawn, prior to initiation of the research, of plans for the research and its risks and expected benefits.

5.1.4 Public disclosure of sufficient information following completion of the clinical investigation to apprise the community and researchers of the study, including the demographic characteristics of the research population, and its results.

5.1.5 Committing to, and documenting attempts to providing informed consent to subjects (or the LAR if the subject is unable to consent, or a family member if the LAR is unavailable) if feasible within the therapeutic window.

5.1.6 Informing the subject (or the LAR or family member as soon as they are available) about the research and the option to discontinue at any time without penalty or loss of benefits as soon as feasible if the subject’s condition improves.

5.1.6.1 If an individual is entered into a clinical investigation with waived consent
and then dies before a LAR or family member can be contacted, information about
the clinical investigation is to be provided to the subject's LAR or family member, if
feasible.

5.1.7 Establishing an independent data monitoring committee to exercise oversight of the
clinical investigation.

5.2 Institutional Review Board responsibilities include:

5.2.1 Review of proposed plan for emergency research involving human subjects to ensure
all criteria in 21 CFR 50.24 are met when the research is FDA-regulated.

5.2.2 Review of proposed plan for emergency research involving human subjects to ensure
relevant criteria in 45 CFR 46 are met when the research is not FDA-regulated.

5.2.3 Review and, if appropriate, approve the investigator's justification for waiving
informed consent by assessing whether:

5.2.3.1 The clinical investigation could not practicably be carried out without the
waiver of consent.

5.2.3.2 The subjects will not be able to give their informed consent as a results of
their medical condition

5.2.3.3 The intervention under investigation must be administered before consent
from the subjects LAR is feasible

5.2.3.4 There is no reasonable way to identify prospectively the individuals likely to
become eligible for participation in the clinical investigation.

5.2.4 Review the consent document and procedures to be used to consent subjects (if
able) and/or their LAR/family member as soon as possible along with the
procedures to ensure the subject (if able) and/or LAR/family member can object to
the subject’s participation.

5.2.5 Review and approve, if appropriate, procedures for ensuring all reasonable efforts
are made to obtain proxy or surrogate informed consent to protect the rights of
subjects from whom informed consent cannot be obtained.

5.2.6 At its discretion, participate in the activities planned for public disclosure to the
communities in which the research will be conducted, and from which subjects will
be drawn, of the research and its possible benefits and risks.

5.2.7 Verifying participation in the research holds out the prospect of direct benefit to the
subjects because:

5.2.7.1 subjects are facing a life-threatening situation that necessitates intervention;

5.2.7.2 appropriate animal and other preclinical studies have been conducted, and
the information derived from those studies and related evidence support the
potential for the intervention to provide a direct benefit to the individual subjects;
and

5.2.7.3 risks associated with the investigation are reasonable in relation to what is
known about the medical condition of the potential class of subjects, the risks and
benefits of standard therapy, if any, and what is known about the risks and benefits
of the proposed intervention or activity.

5.2.8 If an IRB determines that it cannot approve a clinical investigation because the
investigation does not meet the applicable criteria, the IRB must document its
findings and provide these findings promptly in writing to the clinical investigator
and to the sponsor of the clinical investigation.
5.3 Human Research Protections Director responsibilities include:
5.3.1 Ensuring compliance with this policy including verification that a licensed physician
(either as an unconflicted IRB member or consultant) has concurred that a clinical
investigation meets the criteria for waiving consent in planned emergency research.
5.3.2 Providing, or making available, appropriate tools/resources for review of planned
emergency research based on new and evolving applicable regulations and guidelines.
5.3.3 Assisting the UMCIRB committee/chair in the review of submissions, as needed.
5.3.4 Maintaining records of UMCIRB determinations for at least 3 years after completion
of the clinical investigation and making them accessible to federal regulatory agencies
upon request.

5.4 The IRB Chairperson or designee responsibilities include:
5.4.1 Review of IRB submission to determine that the planned emergency research meets
the federal criteria for emergency use in accordance with DHHS and FDA
regulations.
5.4.2 Ensuring appropriate review by the committee is conducted and the results of the
outcome of the review are communicated to the investigator.

5.5 UMCIRB office staff responsibilities include:
5.5.1 Consulting with investigators regarding their IRB submission information.
5.5.2 Composing written documentation of IRB committee determinations and
forwarding this documentation to the research team.
5.5.3 Assisting investigators in explaining human research protections at community or
town hall meetings, if needed.

Revision History:

<table>
<thead>
<tr>
<th>Date</th>
<th>Change</th>
<th>Reference Section(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.13.14</td>
<td>Revised format to standalone SOP.</td>
<td>All Sections</td>
</tr>
<tr>
<td>1.15.20</td>
<td>Updated UMCIRB office name/positions; added definitions related to community/community consults; clarified requirements of investigators and UMCIRB</td>
<td>Section 1.0-4.0, 5.1-5.3, 5.5</td>
</tr>
</tbody>
</table>

References:

DHHS, OHRP. Code of Federal Regulations:  
http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html

http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcr/CFRSearch.cfm?CFRPart=50 and
